retatrutide peptide vs semaglutide retatrutide peptide vs semaglutide PDB-101: Molecule of the Month: GLP-1 Receptor Agonists Semaglutide vs. Tirzepatide vs. Retatrutide:

Jain SK et al

10.3390/ph14100991 43

Some commonly reported side effects of DPP-4 inhibitors noted in clinical trials include upper respiratory tract infection, urinary tract infection (UTI), nasopharyngitis, and headache ( Table 3 )

Clinical guidelines generally recommend GLP-1-based therapies for adults with obesity, usually defined as a BMI above 30, or for overweight patients with additional health risks such as type 2 diabetes, high blood pressure, fatty liver disease, sleep apnoea or cardiovascular complications

Meanwhile, U.S.-based patients who took Trulicity have been hospitalized because of slowing or stopping of the gut, new or worsening pancreatic problems, and other complications

References Gloire, G., Legrand-Poels, S